Cidara Therapeutics CDTX Stock
Cidara Therapeutics Price Chart
Cidara Therapeutics CDTX Financial and Trading Overview
| Cidara Therapeutics stock price | 16.52 USD |
| Previous Close | 1.15 USD |
| Open | 1.15 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 4000 |
| Day's Range | 1.13 - 1.18 USD |
| 52 Week Range | 0.43 - 2.1 USD |
| Volume | 825.38K USD |
| Avg. Volume | 2.37M USD |
| Market Cap | 102.63M USD |
| Beta (5Y Monthly) | 1.295422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -26.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
CDTX Valuation Measures
| Enterprise Value | 55.65M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8688524 |
| PEG Ratio (5 yr expected) | -0.09 |
| Price/Sales (ttm) | 1.2339782 |
| Price/Book (mrq) | 3.825503 |
| Enterprise Value/Revenue | 0.669 |
| Enterprise Value/EBITDA | -6.67 |
Trading Information
Cidara Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.295422 |
| 52-Week Change | 140.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.1 USD |
| 52 Week Low | 0.43 USD |
| 50-Day Moving Average | 1.18 USD |
| 200-Day Moving Average | 1.01 USD |
CDTX Share Statistics
| Avg. Volume (3 month) | 2.37M USD |
| Avg. Daily Volume (10-Days) | 740.19K USD |
| Shares Outstanding | 90.03M |
| Float | 70.28M |
| Short Ratio | 1.43 |
| % Held by Insiders | 9.46% |
| % Held by Institutions | 32.24% |
| Shares Short | 1.91M |
| Short % of Float | 2.14% |
| Short % of Shares Outstanding | 2.12% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -9.99% |
| Operating Margin (ttm) | -10.19% |
| Gross Margin | 10.94% |
| EBITDA Margin | -10.032% |
Management Effectiveness
| Return on Assets (ttm) | -7.73% |
| Return on Equity (ttm) | -52.26% |
Income Statement
| Revenue (ttm) | 83.17M USD |
| Revenue Per Share (ttm) | 1.15 USD |
| Quarterly Revenue Growth (yoy) | 265.60% |
| Gross Profit (ttm) | -11232000 USD |
| EBITDA | -8344000 USD |
| Net Income Avi to Common (ttm) | -8986000 USD |
| Diluted EPS (ttm) | -0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 47.98M USD |
| Total Cash Per Share (mrq) | 0.53 USD |
| Total Debt (mrq) | 1M USD |
| Total Debt/Equity (mrq) | 3.73 USD |
| Current Ratio (mrq) | 2.229 |
| Book Value Per Share (mrq) | 0.298 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -15763000 USD |
| Levered Free Cash Flow (ttm) | -11463000 USD |
Profile of Cidara Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 6310 Nancy Ridge Drive |
| ZIP | 92121 |
| Phone | 858 752 6170 |
| Website | https://www.cidara.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 73 |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Q&A For Cidara Therapeutics Stock
What is a current CDTX stock price?
Cidara Therapeutics CDTX stock price today per share is 16.52 USD.
How to purchase Cidara Therapeutics stock?
You can buy CDTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cidara Therapeutics?
The stock symbol or ticker of Cidara Therapeutics is CDTX.
Which industry does the Cidara Therapeutics company belong to?
The Cidara Therapeutics industry is Biotechnology.
How many shares does Cidara Therapeutics have in circulation?
The max supply of Cidara Therapeutics shares is 10.95M.
What is Cidara Therapeutics Price to Earnings Ratio (PE Ratio)?
Cidara Therapeutics PE Ratio is now.
What was Cidara Therapeutics earnings per share over the trailing 12 months (TTM)?
Cidara Therapeutics EPS is -26.82 USD over the trailing 12 months.
Which sector does the Cidara Therapeutics company belong to?
The Cidara Therapeutics sector is Healthcare.
Cidara Therapeutics CDTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
| NASDAQ Composite Total Return I XCMP | 19098.57 USD — |
+0.1
|
— — | 18095.83 USD — | 19941.93 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}